🔴 Pacific Biosciences is trading 6.7% down today amid biotech-sector weakness

Pacific Biosciences is trading at $2.68, down 6.69%, with biotech-sector weakness a possible contributor.

• The XBI is down 2.50%, while major U.S. indices are higher.
• On October 6, PacBio announced a collaboration with TychoBio to generate RNA-sequencing data for rare-disease therapy models. The announcement is positive in scope but does not explain the drop.
• Available reporting identified no clear company-specific negative catalyst; the move is most consistent with sector pressure, not the broader market’s advance.